These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 26894859)

  • 1. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.
    Schmidt M; Mock A; Jungk C; Sahm F; Ull AT; Warta R; Lamszus K; Gousias K; Ketter R; Roesch S; Rapp C; Schefzyk S; Urbschat S; Lahrmann B; Kessler AF; Löhr M; Senft C; Grabe N; Reuss D; Beckhove P; Westphal M; von Deimling A; Unterberg A; Simon M; Herold-Mende C
    Oncotarget; 2016 Mar; 7(12):14551-68. PubMed ID: 26894859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
    Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
    Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas.
    Skiriute D; Tamasauskas S; Asmoniene V; Saferis V; Skauminas K; Deltuva V; Tamasauskas A
    J Neurooncol; 2011 Mar; 102(1):89-94. PubMed ID: 20607352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.
    Pérez-Magán E; Rodríguez de Lope A; Ribalta T; Ruano Y; Campos-Martín Y; Pérez-Bautista G; García JF; García-Claver A; Fiaño C; Hernández-Moneo JL; Mollejo M; Meléndez B
    Neuro Oncol; 2010 Dec; 12(12):1278-90. PubMed ID: 20685720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
    Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
    Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
    Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
    Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic changes with prognostic value in histologically benign meningiomas.
    Barbera S; San Miguel T; Gil-Benso R; Muñoz-Hidalgo L; Roldan P; Gonzalez-Darder J; Cerda-Nicolas M; Lopez-Gines C
    Clin Neuropathol; 2013; 32(4):311-7. PubMed ID: 23442303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular biological determinations of meningioma progression and recurrence.
    Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
    PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
    Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures.
    Collord G; Tarpey P; Kurbatova N; Martincorena I; Moran S; Castro M; Nagy T; Bignell G; Maura F; Young MD; Berna J; Tubio JMC; McMurran CE; Young AMH; Sanders M; Noorani I; Price SJ; Watts C; Leipnitz E; Kirsch M; Schackert G; Pearson D; Devadass A; Ram Z; Collins VP; Allinson K; Jenkinson MD; Zakaria R; Syed K; Hanemann CO; Dunn J; McDermott MW; Kirollos RW; Vassiliou GS; Esteller M; Behjati S; Brazma A; Santarius T; McDermott U
    Sci Rep; 2018 Sep; 8(1):13537. PubMed ID: 30202034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression.
    Ke HL; Ke RH; Li ST; Li B; Lu HT; Wang XQ
    J Neurooncol; 2013 Jun; 113(2):327-32. PubMed ID: 23525949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic alterations associated with progression and recurrence in meningiomas.
    Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
    J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
    Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
    Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter mutations in primary and secondary WHO grade III meningioma.
    Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
    Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsins B and L and their inhibitors stefin B and cystatin C as markers for malignant progression of benign meningiomas.
    Trinkaus M; Vranic A; Dolenc VV; Lah TT
    Int J Biol Markers; 2005; 20(1):50-9. PubMed ID: 15832773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
    Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
    Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WHO grade II and III meningiomas: a study of prognostic factors.
    Durand A; Labrousse F; Jouvet A; Bauchet L; Kalamaridès M; Menei P; Deruty R; Moreau JJ; Fèvre-Montange M; Guyotat J
    J Neurooncol; 2009 Dec; 95(3):367-375. PubMed ID: 19562258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur.
    San-Miguel T; Navarro L; Megías J; Muñoz-Hidalgo L; Gil-Benso R; Roldán P; López-Ginés C; Cerdá-Nicolás M
    Hum Pathol; 2019 Feb; 84():105-114. PubMed ID: 30261191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of 1p and 14q status, MIB-1 labeling index and progesterone receptor immunoexpression in meningiomas: Adjuncts to histopathological grading and predictors of aggressive behavior.
    Kumar S; Kakkar A; Suri V; Kumar A; Bhagat U; Sharma MC; Singh M; Suri A; Sarkar C
    Neurol India; 2014; 62(4):376-82. PubMed ID: 25237942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.